A US reseller purchased 15 kits of 5000 IU HCG from Homopeptide. He submitted samples to Vanguard Laboratories for independent testing. According to the report, it contained approximately 3,000 IU rather than the claimed 5,000 IU. The sample also failed sterility testing after growth was detected.
The reseller informed Angelina at Homopeptide of the results. Her response was to challenge the results, by sending him a Janoshik COA for HCG showing a result of approximately 6,497 IU, dated 5 January 2026.
There was, however, a rather obvious difference between the product tested on that report and the kits the reseller had actually received. The sample pictured on the Janoshik COA had a red cap. The reseller’s vials had white caps.
The Colour-Changing-Cap Explanation
When the reseller questioned the difference, Homopeptide explained:
“When we ship from China to overseas warehouses, all products will be uniformly replaced with white covers and placed in unified boxes.”
Asked why anyone would routinely replace the caps on finished peptide vials before placing them in a US warehouse, the response was:
“Dear, this is the standard procedure for our shipments from China to overseas warehouses.”
Apparently, changing the caps on finished injectable products is now part of international logistics.
The independent Vanguard result indicated approximately 3,000 IU and detected microbial growth. The Janoshik COA supplied by Homopeptide showed approximately 6,497 IU from a visually different vial. The two reports weren’t simply slightly different. They described two very different products.
The Refund
The reseller eventually received a full refund for the 15 kits, but said this only happened after he spoke to Homopeptide’s “boss,” identified as Zimo Lee. The money spent on the independent testing wasn’t reimbursed.
At Homopeptide’s request, the reseller returned all 15 kits to the company’s US warehouse. According to the reseller, once the returned stock had been received, the number of HCG kits shown on the US warehouse price list increased by exactly 15.
He didn’t take before-and-after screenshots because he was not expecting the inventory to change. He therefore acknowledged that he can’t substantiate what he observed. It’s not proof that the returned HCG was placed back on sale, but it’s certainly suspicious.
Final Thought
The reseller eventually recovered the purchase price, but the testing fee was left to him, and the eventual destination of the 15 returned kits remains unknown.
Comments